Innosera

Innosera ApS is a newly established company under Danish law, created solely for the purpose of acquiring Bavarian Nordic A/S in collaboration with Nordic Capital and Permira. It is not a stand-alone operating biotechnology or pharmaceutical company, but rather a special purpose vehicle under the control of these two private equity firms[2][3][6]. As of the latest available information, all regulatory approvals have been obtained for the recommended public tender offer for Bavarian Nordic—a global vaccine company specializing in vaccines for diseases such as mpox (monkeypox) and smallpox, with a leading portfolio of travel vaccines[1][3][5]. The offer is to acquire all outstanding shares of Bavarian Nordic at DKK 233 per share, and the transaction is now subject to shareholder approval[1][3].